Business
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System
About this update from Vor Biopharma Inc.
[{"type":"text","content":"VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2021, and provided a business update. “Our main focus during the third quarter of 2021 has been on site activation and patient recruitment in the Phase 1/2a trial of VOR33 for patients with AML. The initial data from this trial, expected in the first half of 2022, is intended to provide first-in-human demonstration of CD33 biological redundancy,” said Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer. “In addition to advancing our lead program, we are excited to expand our pipeline to include multiplexing and the nomination of our first multiplex-edited eHSC candidate and first multi-specific CAR-T candidate. We also continue to make progress on the build-out of our internal manufacturing facility which will support the development of our pipeline as we work towards our mission of curing blood cancers through cell and genome engineering.” Corporate Highlights Continued progress on study enrollment and site activation for clinical trial of VOR33 in patients with AML. VOR33 is the Company’s lead product candidate consisting of genome-edited hematopoietic stem and progenitor cells that have been engineered to lack the CD33 protein. It is designed to offer an alternative to the standard of care in transplant settings for patients suffering from AML and potentially other blood cancers. The Phase 1/2a trial is actively enrolling and recruiting patients. The Company plans to report initial clinical data in the first half of 2022, which will include enrollment progress and initial engraftment on patients enrolled to date. Neutrophil engraftment by day 28 is the primary endpoint of the trial.In September, VOR33 received Fast Track designation for the treatment of AML from the U.S. Food and Drug Administration (FDA) allowing for potential facilitated development and expedited review process. Announced first multi-targeted Treatment System comprising VOR33-CLL1 multiplex-edited eHSC therapy and VCAR33-CLL1 multi-spe...